Previous Article | Next Article 
J Virol, February 1998, p. 1115-1121, Vol. 72, No. 2
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
A New System for Stringent, High-Titer Vesicular
Stomatitis Virus G Protein-Pseudotyped Retrovirus
Vector Induction by Introduction of Cre Recombinase into Stable
Prepackaging Cell Lines
Tohru
Arai,1,2
Kazuyuki
Matsumoto,1
Kanako
Saitoh,1
Motoyasu
Ui,1
Taiji
Ito,1
Masao
Murakami,1
Yumi
Kanegae,3
Izumu
Saito,3
François-Loïc
Cosset,4
Yasuhiro
Takeuchi,5 and
Hideo
Iba1,*
Department of Gene
Regulation1 and
Laboratory of Molecular
Genetics,3 Institute of Medical Science,
University of Tokyo, Minato-ku, Tokyo 108, and
Tsukuba Research
Laboratories, Eisai Co., Ltd., Tsukuba-shi, Ibaraki
300-26,2 Japan;
CGMC, CNRS UMR106,
Universite Claude Bernard Lyon-1, 69622 Villeurbanne Cedex,
France4; and
Institute of Cancer
Research, Chester Beatty Laboratories, London SW3 6JB, United
Kingdom5
Received 16 June 1997/Accepted 21 October 1997
 |
ABSTRACT |
We report here on stable prepackaging cell lines which can be
converted into packaging cell lines for high-titer vesicular stomatitis
virus G protein (VSV-G)-pseudotyped retrovirus vectors by the
introduction of Cre recombinase-expressing adenovirus. The generated
prepackaging cell lines constitutively express the gag-pol
genes and contain an inducible transcriptional unit for the VSV-G gene.
From this unit, the introduced Cre recombinase excised both a neomycin
resistance (Neor) gene and a poly(A) signal flanked by a
tandem pair of loxP sequences and induced transcription of
the VSV-G gene from the same promoter as had been used for
Neor expression. By inserting an mRNA-destabilizing signal
into the 3' untranslated region of the Neor gene to reduce
the amount of Neor transcript, we were able efficiently to
select the clones capable of inducing VSV-G at high levels. Without the
introduction of Cre recombinase, these cell lines produce neither VSV-G
nor any detectable infectious virus at all, even after the transduction of a murine leukemia virus-based retrovirus vector encoding
-galactosidase. They reproducibly produced high-titer virus stocks
of VSV-G-pseudotyped retrovirus (1.0 × 106 infectious
units/ml) from 3 days after the introduction of Cre recombinase. We
also present evidence that VSV-G-producing cells are still fully
susceptible to transduction by VSV-G pseudotypes. However, in this
vector-producing system, which regulates VSV-G pseudotype production in
an all-or-none manner, the integration of vector DNA into packaging
cell lines would be minimized. We further show that heparin
significantly inhibits retransduction of VSV-G pseudotypes in the
culture fluids of packaging cell lines, leading to a two- to fourfold
increase in the yield of the pseudotypes after induction. This
vector-producing system was very stable and should be advantageous in
human gene therapy.
 |
INTRODUCTION |
Vectors based on murine leukemia
virus (MLV) have been developed and used as powerful tools for gene
transfer in basic research as well as human gene therapy. However, some
problems remain, such as relatively low titers, a poor transducibility
into some kinds of cells, and the inability to transfer genes into
nondividing cells (17, 19, 20, 23). When this retrovirus
vector is pseudotyped with the G protein of vesicular stomatitis virus
(VSV-G) (34), it has a much broader host range than the
vectors having the conventional amphotropic Env, and the titers of the
virus stocks can be concentrated about 1,000 times by
ultracentrifugation (4, 9, 37). Expression of VSV-G protein,
however, is cytotoxic for most mammalian cells and imposes a
significant growth disadvantage. Pseudotyped vector titers of
105 to 106 infectious units (IU)/ml have been
recovered after the transient expression of the VSV-G gene by DNA
transfection into cell lines which were constitutively expressing the
gag and pol genes, but these systems are not
suitable for the reproducible preparation of certified vectors on a
large scale. Because of the cytotoxicity of VSV-G, generation of stable
packaging cell lines for the production of such pseudotyped vectors has
been difficult, despite their potential advantages for gene transfer.
To overcome this problem, some stable packaging cell lines (6,
22) or virus-producing cell lines (36) for VSV-G
pseudotypes have been developed by using tetracycline-modulated
promoters for the VSV-G expression. These cell lines have been reported
to induce high titers of pseudotypes (106 to
107 IU/ml) by the removal of tetracycline.
However, these stable cell lines were reported to produce low titers
(101 to 102 IU/ml [6] or
103 to 104 IU/ml [22]) of
pseudotypes even in the presence of transcriptional repressors such as
tetracycline. Since the receptor for VSV-G is reported to include
ubiquitous anionic phospholipids such as phosphatidylserine (18,
28), this leaky virus production by these packaging cell lines
before the induction of the VSV-G gene could potentially cause virus
reentry into the cell culture and accumulation of the vector DNA in the
chromosomes during the process of selection and subsequent passages of
the packaging cell lines harboring the virus vector.
To overcome this problem, we present here a new system that is suitable
for the production of VSV-G pseudotypes on a large scale. In this
system, we first constructed prepackaging cell lines which express the
gag-pol genes and harbor a completely silent VSV-G gene.
These prepackaging cell lines were designed to be converted into
packaging cell lines producing VSV-G at a high level. This conversion
was carried out via loxP-specific recombination by Cre
recombinase introduced by a replication-defective adenovirus vector. We
show here that the prepackaging cell lines harboring a virus vector
produce no detectable transducing particles but produce high titers
(~106 IU/ml) of VSV-G pseudotypes after the introduction
of Cre recombinase. We also present evidence that cells producing
VSV-G proteins are fully susceptible to the VSV-G
pseudotypes, which confirms the advantage of our pseudotype production
system, which regulates production in an all-or-none manner, over other
inducible cell lines.
 |
MATERIALS AND METHODS |
Plasmid construction.
The entire VSV-G (Indiana
serotype)-coding fragment (24) was excised from pSVGL
(25) by EcoRI digestion, blunt ended by Klenow
treatment, and inserted into the unique SwaI site in pCALNLw (15, 16) to generate pCALNLG (Fig.
1A). The fragment encoding chicken
c-fos was excised from chicken c-fos genomic
clone no. 7 (11) by BglII digestion, blunt ended
by Klenow treatment, and further digested with ClaI to
excise a 0.4-kb fragment containing an mRNA-destabilizing signal.
pCALNLw was digested at the single ClaI site, blunt ended by
Klenow treatment, and self-ligated to create an NruI site.
The generated plasmid was completely digested with both NspV
and NruI and ligated with the 0.4-kb fragment containing the
mRNA-destabilizing signal in the 3' untranslated region of the
Neor gene (2) to generate pCALNdLw. The fragment
containing the Neor gene with the mRNA-destabilizing signal
was excised from pCALNdLw by MluI digestion and was inserted
into the MluI site of pCALNLG digested with MluI
to replace the conventional Neor gene, generating pCALNdLG
(Fig. 1A).

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 1.
Plasmid structure for the generation of prepackaging
cell lines and system for Cre-mediated pseudotyped retrovirus
production. (A) Structures of pCALNLG and pCALNdLG. Two loxP
sequences are tandemly located in each plasmid. CAG, CAG promoter; Neo,
neomycin resistance gene; pA, polyadenylation signal; VSV-G,
VSV-G (Indiana serotype)-coding sequence. The mRNA-destabilizing signal
was derived from the 3' untranslated region of chicken
c-fos. (B) Schematic presentation of the conversion from the
prepackaging cell line to the packaging cell line. In the prepackaging
cell line generated by the transfection of pCALNdLG into FLY, the
Neor gene is transcribed from a CAG promoter, while the
VSV-G gene is completely silent because the RNA transcript terminates
before its coding sequence. Arrows indicate the predicted transcript.
The Neor transcript is expected to be unstable because it
contains the mRNA-destabilizing signal. Cre recombinase excises the
Neor gene, the mRNA-destabilizing signal, and the poly(A)
signal by site-specific recombination between the two loxP
sequences and thus converts the prepackaging cell line to the packaging
cell line. In the packaging cell line, the VSV-G gene is now
transcribed by the same promoter that was used for the Neor
expression. MoLTR, MoMLV long terminal repeat; MoMLV
gag-pol, MoMLV gag and pol genes;
bsr, blasticidin resistance gene; pA, polyadenylation
signal; , packaging signal of retrovirus vector; X gene,
an arbitrary gene (here we used the gene encoding -galactosidase
with a nuclear localization signal).
|
|
Cell lines and drug selection.
FLY cells (8) (a
derivative of human fibrosarcoma cell line HT 1080, which carries the
gag and pol genes from Moloney MLV [MoMLV]),
3YI (rat fibroblast) cells, and 293 (human embryonal kidney) cells were
maintained in Dulbecco's modified Eagle's medium (high glucose)
supplemented with 10% fetal calf serum and kept at 37°C. FLY cells
and derivatives were always grown in the presence of 4 µg of
blasticidin S (Funakoshi) per ml, and drug selections of transfected
FLY cells were performed with 1.0 mg of G418 (Gibco/BRL) per ml.
Mus dunni tail fibroblast cells and PG-4
S+L
cells (Moloney sarcoma virus-infected
G355 cat cells) were grown in McCoy's 5A medium supplemented with 10%
fetal calf serum.
DNA transfection and cloning of the transfectants.
FLY cells
(5 × 105 cells/100-mm-diameter dish) were seeded at 1 day before transfection and transfected with pCALNdLG or pCALNLG (10 to
30 µg) by the calcium phosphate method (5). Two days after
transfection, the cell cultures were split at several ratios, and G418
(final concentration, 1 mg/ml) was added to the medium 3 days after
transfection for the selection of stable transformants. G418-resistant
colonies were picked up with cloning cylinders and transferred for
growth.
Retrovirus transduction, concentration, and titration.
To
transduce an MLV-based retrovirus vector encoding
-galactosidase
with a nuclear localization signal (MFGnlslacZ) into selected clones,
stocks of the amphotropic virus vector were collected from FLYA4lacZ3
cells (8). Transduction was carried out in the presence of
Polybrene (Sigma) (8 µg/ml) 1 day after passage. For the titration of
amphotropic MFGnlslacZ or VSV-G-pseudotyped MFGnlslacZ, 3Y1 cells were
plated at 1.5 × 103 cells/well in 96-well plates 1 day before transduction and incubated for 3 days with serial dilutions
of virus supernatants containing 8 µg of Polybrene per ml. Transduced
3Y1 cells were fixed with 1.25% glutaraldehyde and stained with 5 mM
K4[Fe(CN)6]-5 mM
K3[Fe(CN)6]-2 mM MgCl2-1 mg of
X-Gal (5-bromo-4-chloro-3-indolyl-
-D-galactopyranoside) (Wako) per ml for more than 4 h, and then the numbers of cell clones with blue-stained nuclei were counted.
Adenovirus vector infection for pseudotyped retrovirus
production.
Prepackaging cells were seeded at 3 × 104 cells/well in 24-well plates; 1 day later, they were
infected with AxCANCre at various multiplicities of infection (MOIs)
for 1 h in 100 µl of the culture medium to promote infection and
then were cultured in a volume of 500 µl as usual. G418 was removed
from the culture medium just after the AxCANCre infection. In some
experiments, the culture temperature was changed to 32°C 2 days after
infection. The medium was changed every day, and at each medium change
the cells were washed three times with the medium to minimize
contamination of the unabsorbed adenovirus vector. Southern blotting
analysis was performed as follows. Total chromosome DNA was prepared by
standard techniques (27) from PtG-S2 and PtG-L1 before or 4 days after AxCANCre infection. The digested DNA was transferred
to a nylon membrane (Hybond N+; Amersham) by the capillary transfer
method. The probe was labeled with 32P, and hybridized DNA
was detected by autoradiography.
Protein analysis.
Expression of VSV-G protein was evaluated
by immunocytochemical staining with murine monoclonal anti-VSV-G
immunoglobulin G (IgG) (P5D4; Sigma). Cells were fixed with
phosphate-buffered saline containing 3% paraformaldehyde and 0.1%
Triton X-100 at 4°C for 15 min, and then a 1:3,000 dilution of
monoclonal anti-VSV-G IgG was added. VSV-G-producing cells were
visualized by using biotinylated anti-mouse IgG and a Vectastain ABC
kit (Vector). For Western blot analysis, cellular lysates were prepared
under denaturing conditions and separated by sodium dodecyl
sulfate-10% polyacrylamide gel electrophoresis. The gels were
transferred onto polyvinylidene difluoride membranes (Immobilon;
Millipore) with a semidry electroblotter. Filters were immunoblotted
with monoclonal anti-VSV-G (Sigma) IgG or anti-Neor (5Prime
to 3Prime) and then biotinylated anti-mouse IgG. Protein bands were
detected with an ECL kit (Amersham).
 |
RESULTS |
Strategy for the generation and activation of the prepackaging cell
lines.
For the generation of prepackaging cell lines, we made use
of a human cell line, FLY, which expresses the gag and
pol genes of MoMLV at a high level. It was previously shown
that retroviruses produced from human-derived cell lines are much more
resistant to human serum than those produced by conventional
murine-derived packaging cell lines, due to the humanized glycosylation
pattern of the virus envelope protein (8, 31-33). For the
efficient screening of prepackaging cell lines capable of inducing high levels of VSV-G after the introduction of Cre recombinase, we designed
a plasmid, pCALNdLG (Fig. 1A), for the generation of prepackaging cell
lines from FLY cells. In pCALNdLG, the VSV-G gene is preceded by the
Neor gene flanked by a tandem pair of loxP
sequences. The transcription of the Neor gene is designed
to be driven from a CAG promoter (the chicken
-actin gene promoter
connected with the cytomegalovirus immediate-early promoter
[21]) present upstream of the 5' loxP
sequence and to be terminated by a poly(A) signal located upstream of
the 3' loxP sequence. Therefore, the VSV-G gene should not
be transcribed from the CAG promoter or any other promoter in
G418-resistant clones. Since the 3' untranslated region of the
Neor transcripts from pCALNdLG includes an
mRNA-destabilizing sequence originated from the 3' noncoding sequence
of the chicken c-fos gene, the relative amount of the
Neor transcripts would be reduced. When FLY cells are
exposed to G418 after transfection with pCALNdLG, we can efficiently
select cell lines in which the synthesis of the transcripts from the
CAG promoters is sufficiently active to keep the unstable
Neor transcript at high levels adequate for survival.
After site-specific recombination between the pair of loxP
sequences by Cre recombinase, the Neor gene, the
mRNA-destabilizing sequence, and the poly(A) signal would be removed
from the chromosomal DNA as a closed circular molecule and the CAG
promoter would be available for the active transcription of the VSV-G
gene (Fig. 1B) to produce VSV-G pseudotypes. To assess the validity of
this design, we also constructed pCALNLG (Fig. 1A), in which the
mRNA-destabilizing signal was deleted from pCALNdLG, and compared the
selection efficiencies.
For the introduction of Cre recombinase into the prepackaging
cell lines to convert them into packaging cell lines, we chose
to
use a replication-defective adenovirus vector, AxCANCre,
which
encodes Cre recombinase tagged with a nuclear localization signal
(
12,
15,
16). This vector has been shown to be efficiently
introduced into human cells, to induce this exogenous gene at
a very
high level within a short time after the infection, and
to cause
efficient excision between a pair of
loxP sequences located
on another adenovirus genome and on a cellular chromosome.
Cloning of the prepackaging cell line.
By using the calcium
phosphate method, either pCALNdLG or pCALNLG was transfected into a
pair of FLY cultures. One day after the transfection, the cultures were
split and stable transformants were selected with G418 for 2 weeks;
surviving colonies were stained with crystal violet. The colony number
of pCALNdLG transfectants was about one-third of that of the pCALNLG
transfectants, suggesting that the Neor transcript
from pCALNdLG is less stable, as expected (data not shown). In
preliminary experiments, several clones were isolated from both of the
transfectants and parallel cultures of each clone were infected with
the adenovirus vectors at an MOI of 10 to determine the inducibility of
VSV-G protein expression by immunocytochemical staining. The appearance
of clones capable of VSV-G induction at a high level was more frequent
in pCALNdLG transfectants (3 of 11 transfectants) than in pCALNLG
transfectants (1 of 25). In each positive clone, almost the entire
population was shown to express VSV-G protein, indicating that the
introduction of Cre recombinase is very efficient. These results
indicate that pCALNdLG is effective for isolation of clones that
produce high levels of VSV-G protein after site-specific recombination
and support the feasibility of screening with pCALNdLG. For these reasons, we chose pCALNdLG for the transfection experiments for large-scale screening. We selected 26 clones that express high levels
of VSV-G protein after induction as candidates for the prepackaging
cell lines. The only clone among the pCALNLG transfectants (PtG-L1)
which produced VSV-G at a comparable level was also used for further
experiments, for comparison.
Isolation of prepackaging cell lines capable of inducing high-titer
VSV-G pseudotypes.
Parallel cultures of the above-described clones
(27 in all) were transduced with amphotropic MFGnlslacZ virus at an MOI
of 3. This virus vector carries the nlslacZ gene, which encodes
-galactosidase with a nuclear localization signal (nlsLacZ) as a
marker enzyme. The efficiency of transduction was high as judged from
cytochemical staining for the LacZ product (more than 85%). These
transduced cultures were infected with AxCANCre at an MOI of 10. Culture fluids were collected, and the virus titers were determined
with 3Y1 rat fibroblasts as the indicator. All the clones produced virus with various titers. Two clones produced more than 5 × 105 IU/ml, and 13 clones produced more than 5 × 104 IU/ml. We selected one clone (PtG-S2) among 26 clones
of pCALNdLG transfectants, because it produced the highest virus
titers. Virus induction by PtG-L1 was modest (2 × 104
IU/ml). When the virus stocks obtained from these two cell lines were
treated with anti-VSV-G (Indiana serotype) antiserum, the virus was
neutralized completely (unpublished observations).
Efficient and precise site-specific recombination in the PtG-S2
chromosome after the introduction of AxCANCre.
Southern blot
analysis of PtG-S2 (or PtG-L1) chromosomal DNA was performed to test
whether the loxP-specific recombination occurred as expected
after the introduction of Cre recombinase. Chromosomal DNA was isolated
before or 4 days after the AxCANCre introduction and digested with
NcoI, which recognizes three sites in pCALNdLG (or pCALNLG),
and DNA fragments containing the VSV-G gene were detected (Fig.
2A). A single 1.5-kb (or 1.2-kb) band was
detected in prepackaging cells, but it mostly disappeared and a new
2.0-kb band appeared instead after the Cre recombinase introduction
(Fig. 2B). This change in the fragment size is consistent with the idea
that Cre recombinase excised the DNA sequence between the two
loxP sequences by recombination. By comparing the densities of the control plasmid DNA charged at various amounts, PtG-L1 was
estimated to contain a single copy of pCALNLG in the diploid cell,
while PtG-S2 harbored three copies of pCALNdLG. This result indicates
that the higher VSV-G expression in PtG-S2 is partly supported by the
gene dosage effects.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 2.
Southern blot analysis of genomic DNA. (A) Physical maps
and predicted structural changes in pCALNdLG after the introduction of
Cre recombinase. In the case of pCALNLG, the predicted NcoI
fragment is 1.2 kb in size because of the lack of the
mRNA-destabilizing signal. The 0.7-kb VSV-G probe was isolated from
pCALNdLG by MluI and NcoI digestion. N,
NcoI sites. (B) Autoradiogram of Southern blotting of
NcoI digests of genomic DNA (15 µg per lane) from PtG-L1
and PtG-S2 before ( ) and 4 days after (+) the introduction of Cre
recombinase (right) and of plasmid pCALNdLG DNA for quantitation
(left).
|
|
When VSV-G expression levels were analyzed by Western blotting, both
PtG-S2 and PtG-L1 were found to produce no detectable
VSV-G before Cre
recombinase introduction (Fig.
3). Four
days
after AxCANCre introduction, both cell lines clearly produced
VSV-G. However, the VSV-G expression level in PtG-S2 was much
higher
(about 10- to 15-fold) than that in PtG-L1, which is consistent
with
the observation that PtG-S2 is a much more efficient virus
producer.
Since the transcripts for the VSV-G gene from the CAG
promoter in
PtG-L1 and in PtG-S2 are expected to have the same
molecular structure
after the introduction of Cre recombinase,
these results indicate that
the total synthetic rate of the VSV-G
transcript is more than 10-fold
higher in PtG-S2. This higher
synthetic rate can be partly explained by
the gene dosage effect
(threefold), as mentioned above, but also arises
partly from the
enhanced frequency of transcription initiation from the
CAG promoter
in PtG-S2 owing to the integration sites of the plasmid.

View larger version (45K):
[in this window]
[in a new window]
|
FIG. 3.
Protein analysis of VSV-G and the Neor gene
product in PtG-S2 and PtG-L1 cells before and 4 days after AxCANCre
infection. Lysates of PtG-S2 and PtG-L1 cells as well as the parent FLY
cells were prepared under denaturing conditions, separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (20 µg per each
lane), and detected by Western blotting. Sequential dilutions (10, 5, 2.5, and 1.25 µg per lane) of PtG-L1 before induction or of PtG-S2
after induction were analyzed in parallel for quantitation.
|
|
We next analyzed the levels of expression of the Neo
r gene
products by Western blotting with the same cell lysates (Fig.
3).
In
both PtG-S2 and PtG-L1, the Neo
r gene products were
detectable before Cre recombinase introduction
but were marginal 4 days
after the introduction, in accordance
with the observation that most of
these cell lines at this stage
had lost resistance to G418 (data not
shown). It should be pointed
out that the Neo
r expression
level was about threefold higher in PtG-L1 than in
PtG-S2, while the
CAG promoter in PtG-S2 was expected to be stronger
than that in PtG-L1
(as judged from the VSV-G expression levels),
suggesting that the
transcript for the Neo
r gene in PtG-S2 is much less stable
than that in PtG-L1, as expected.
All of these results indicate that
the mRNA-destabilizing sequence
in pCALNdLG was helpful for the
selection of cell lines with a
high total synthetic rate from the CAG
promoter, as desired.
Conditions for optimum virus production.
PtG-S2 and PtG-L1
were transduced with amphotropic MFGnlslacZ virus, and these mixed
populations were further used for screening to determine the
optimum conditions for the induction of virus production from these
prepackaging cell lines. Each AxCANCre should be
introduced into every cell for the loxP-dependent
recombination, and the efficiency of the recombination would be
increased by dosage effects. A high dose of adenovirus, however, would
cause cell damage due to the toxicity of adenovirus itself. Therefore, we next determined the time course of virus production from PtG-S2 after AxCANCre infection at several MOIs. We found the optimum range of
MOIs of adenovirus for the highest induction of retrovirus to be around
10 to 30 (Table 1). Since the growth of
PtG-S2 cells was significantly inhibited at an MOI of more than 30, we
infected PtG-S2 with the adenovirus vector at an MOI of 10 in further
studies. The titer of the virus recovered from PtG-L1 was roughly 1%
of that from PtG-S2 under all of these conditions (data not shown).
We next determined the time course of virus production at either
37 or 32°C after adenovirus infection at an MOI of 10 (Fig.
4). The highest titer for PtG-S2 was
about 1.2 × 10
6 IU/ml at either temperature, and the
induction kinetics were
rather similar at both temperatures.
Growth of the AxCANCre-infected
PtG-S2 cells was
strongly retarded after 4 days postinfection,
and some cytopathic
effects were observed thereafter. To test
the genetic stability of the
prepackaging cell line, the production
of pseudotyped retrovirus was
compared for PtG-S2 freshly grown
from the cellular stocks kept in
liquid N
2 and the same cell line
that had been cultured
continuously for more than 3 months in
the presence of blasticidin S
and G418. The kinetics of virus
induction after AxCANCre introduction
remained unchanged during
the passage of this cell line, and similar
results were obtained
when PtG-L1 was used instead. These results
indicate that the
prepackaging cell lines established here are quite
stable during
cellular proliferation.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 4.
Time course of pseudotyped retrovirus production after
transduction of Cre recombinase. Cre recombinase was transduced into
each clone harboring MFGnlslacZ to induce VSV-G. Virus titers produced
from PtG-S2 with (closed circles) or without (open circles)
transduction with AxCANCre are shown. Cells were cultured at 37°C
continuously (A) or cultured at 37°C until 2 days after transduction
and then transferred to 32°C (B).
|
|
Characterization of VSV-G-pseudotyped retrovirus produced by
prepackaging cell lines.
Virus stocks collected from induced
PtG-S2 were concentrated by ultracentrifugation and titrated. These
stocks could be concentrated to up to 109 IU/ml, with a
yield of more than 80% (data not shown). We also observed that these
virus stocks were more stable in human serum (data not shown), as
expected from a previous report (33). To check whether the
produced virus contains replication-competent retrovirus (1,
13), we incubated M. dunni cells with the pseudotyped
virus stocks containing 5.0 × 106 IU and passaged
them three times. The recovered culture medium was added to the
indicator cell line, PG-4 S+L
, and kept for 5 days. No foci were detected in the culture, indicating that this virus
stock of 5.0 × 106 IU contains less than one particle
of replication-competent retrovirus.
We next tried to detect the adenovirus vector in pseudotyped
retrovirus stocks by using a method reported previously
(
14).
The pseudotyped virus stocks were collected every day
from 3 to
5 days after adenovirus infection. These virus stocks
were accumulated
(total titer, 2.0 × 10
6 IU) and used
to infect 293 cells, which can support the replication
of
AxCANCre. These cells were kept for 12 days but showed no
cytopathic
effects, eliminating the possibility of adenovirus
contamination
in the stock.
VSV-G-producing cells are fully susceptible to
VSV-G-pseudotyped retroviruses.
The receptor for VSV-G has
been reported to include anionic phospholipids, such as
phosphatidylserine (18, 28). We were next interested in
whether cells producing VSV-G could acquire resistance to
VSV-G-pseudotyped retrovirus, as is observed in natural
retroviruses (known as interference). When PtG-S2 or PtG-L1 without any vector genome was infected with MFGnlslacZ pseudotyped with
VSV-G before or 4 days after AxCANCre introduction, almost the
entire cell populations were infected with VSV-G-pseudotyped virus as
judged from lacZ expression, independently of the AxCANCre infection (Fig. 5). We also observed that
the diluted VSV-G pseudotypes (102 to 103
IU/ml) were able to infect both VSV-G-producing and nonproducing cells
at similar infection efficiencies (data not shown). This result
indicates that cells producing VSV-G, whether at low or high levels,
are almost fully susceptible to the infection by VSV-G-pseudotyped
retroviruses and further indicate that the VSV-G receptors were not
saturated, unlike other natural receptors for retroviruses.

View larger version (86K):
[in this window]
[in a new window]
|
FIG. 5.
Transduction of VSV-G-pseudotyped retrovirus into PtG-S2
cells expressing VSV-G. A PtG-S2 culture, which was left uninfected (A)
or was infected with AxCANCre at an MOI of 10 (B), was grown for 3 days
longer and transduced with VSV-G-pseudotyped MFGnlslacZ. Two days after
the transduction, the cells were fixed and cytochemically stained with
X-Gal. Bar, 100 µm.
|
|
This property of VSV-G-producing cells potentially has two
disadvantages for high-quality or high-titer virus production.
The
packaging cell line would accumulate vector DNA in their chromosomes
by
a "self-ping-pong" mechanism, causing their genetic instability,
and recovery of the VSV-G pseudotype retrovirus from the culture
medium
would be reduced by its retransduction into the packaging
cell lines
which produced it. We have screened several reagents
for the ability to
suppress the transduction of the produced packaging
cell lines and
found that heparin (8 U/ml) inhibits the infection
of the VSV-G
pseudotype virus-producing cells drastically (reduced
to less than 15%
in the absence of Polybrene and to less than
2% in the presence of
Polybrene). Immediately after this heparin-containing
virus stock was
diluted 10-fold with the medium, virus infectivity
was fully recovered,
indicating that this suppression is reversible.
Indeed, addition of
heparin to the PtG-S2 cultures 2 days after
AxCANCre infection caused a
two- to fourfold increase in the yield
of VSV-G pseudotypes (data not
shown). The heparin were able to
be efficiently removed by subsequent
ultracentrifugation.
 |
DISCUSSION |
We have presented here a unique system for the production of
retrovirus vectors pseudotyped by VSV-G, the expression of which is
cytotoxic for most mammalian cells, including FLY derivatives. In this
study, the retrovirus vector was introduced into the prepackaging human
cell line PtG-S2 by virus transduction, but DNA transfection would be
one alternative. Since the prepackaging cell line contains an inducible
transcriptional unit for the VSV-G gene with use of the Cre
recombinase-loxP system (3, 7, 10, 26, 35), which
is reported to switch the expression in an all-or-none manner (15,
16), we can select cell lines harboring the virus vector without
any leaky production of transducible particles which might cause
genetic instability of the cell lines during the selection and
subsequent passaging procedures. The prepackaging cell line harboring
the virus vector can be stocked in liquid N2 or kept in
culture without any loss of virus-producing activity after the
introduction of Cre recombinase. This genetic stability of the
prepackaging cell lines is at least partly derived from the fact that
the Neor and VSV-G genes are under the control of the same
promoter. When Cre recombinase is introduced, the prepackaging cell
lines are efficiently converted into packaging cell lines producing
retrovirus pseudotyped by VSV-G at titers of more than 1.0 × 106 IU/ml. For the rapid and efficient introduction of Cre
recombinase, we used a replication-defective adenovirus vector. DNA
transfection would be an alternative for the introduction of the Cre
recombinase gene. The fact that the prepackaging cell line originated
from human cells has two advantages: the produced pseudotypes are
resistant to human serum (our unpublished results), and the efficiency
of adenovirus infection was probably higher than that with mouse cell
lines.
For the isolation of prepackaging cell lines that express VSV-G at high
levels after the introduction of Cre recombinase, we designed a system
in which the same promoter is used for the Neor gene for
the selection of prepackaging cell lines and for the VSV-G gene. Four
days after Cre recombinase introduction, the Neor gene was
precisely and almost completely excised from the chromosomal DNA (Fig.
2), resulting in a stringent expressional switch from the
Neor gene to the VSV-G gene (Fig. 1B) as judged by protein
analysis (Fig. 3). To select transfectants that efficiently transcribe the Neor gene at high levels, the Neor
transcript was made very unstable by inserting an mRNA-destabilizing signal (29, 30). We showed here that this cloning design
worked as expected, by comparing this construct and that without the mRNA-destabilizing element. Compared with PtG-L1, which has no mRNA-destabilizing sequence, PtG-S2 produced a smaller amount of
Neor product, while PtG-S2 was converted into a producer
cell line expressing much higher VSV-G levels after Cre recombinase
introduction.
We also showed that cells expressing either a low or a high level of
VSV-G proteins are fully susceptible to infection with VSV-G
pseudotypes, consistent with the report that the VSV-G receptor contains ubiquitous anionic phospholipids. Interference would not be
necessary for a lytic virus such as VSV. This means that a pseudotype
can theoretically infect the same cell that produced it and implies
that the packaging cell lines can accumulate virus vector during cell
growth by a "self-ping-pong" mechanism. Long, leaky production of
the pseudotypes would increase the possibility of genetic changes
of the inducible packaging cell lines before virus induction. We
believe that the pseudotype-producing system presented here is highly
advantageous, in that we can control the VSV-G expression very
stringently in PtG-S2 cells and can suppress the reentry of pseudotype
retrovirus into the PtG-S2 cells by adding heparin. This system should
be suitable for the large-scale production of pseudotypes for human
gene therapy.
 |
ACKNOWLEDGMENTS |
We are grateful to Hidesaburo Hanafusa, Shih-Hui Liong, Satoshi
Okazaki, and Takashi Kameda for helpful discussions. We thank Etsuko
Endo and Michiru Tsukada for assistance in the preparation of the
manuscript.
This work was supported in part by grants and endowments from Eisai
Co., Ltd., and by a Grant-in-Aid for Scientific Research on Priority
Areas from the Ministry of Education, Science and Culture, Japan.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Gene Regulation, Institute of Medical Science, University of Tokyo,
4-6-1 Shirokanedai, Minato-ku, Tokyo 108, Japan. Phone: 81-3-5449-5730. Fax: 81-3-5449-5449. E-mail:
iba{at}hgc.ims.u-tokyo.ac.jp.
 |
REFERENCES |
| 1.
|
Bassin, R. H.,
S. Ruscetti,
I. Ali,
D. K. Haapala, and A. Rein.
1982.
Normal DBA/2 mouse cells synthesize a glycoprotein which interferes with MCF virus infection.
Virology
123:139-151[Medline].
|
| 2.
|
Beck, E.,
G. Ludwig,
E. A. Auerswald,
B. Reiss, and H. Schaller.
1982.
Nucleotide sequence and exact localization of the neomycin phosphotransferase gene from transposon Tn5.
Gene
19:327-336[Medline].
|
| 3.
|
Bergemann, J.,
K. Kühlcke,
B. Fehse,
I. Ratz,
W. Ostertag, and H. Lother.
1995.
Excision of specific DNA-sequences from integrated retroviral vectors via site-specific recombination.
Nucleic Acids Res.
23:4451-4456[Abstract/Free Full Text].
|
| 4.
|
Burns, J. C.,
T. Friedmann,
W. Driever,
M. Burrascano, and J. K. Yee.
1993.
Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells.
Proc. Natl. Acad. Sci. USA
90:8033-8037[Abstract/Free Full Text].
|
| 5.
|
Chen, C., and H. Okayama.
1987.
High-efficiency transformation of mammalian cells by plasmid DNA.
Mol. Cell. Biol.
7:2745-2752[Abstract/Free Full Text].
|
| 6.
|
Chen, S. T.,
A. Iida,
L. Guo,
T. Friedmann, and J. K. Yee.
1996.
Generation of packaging cell lines for pseudotyped retroviral vectors of the G protein of vesicular stomatitis virus by using a modified tetracycline inducible system.
Proc. Natl. Acad. Sci. USA
93:10057-10062[Abstract/Free Full Text].
|
| 7.
|
Choulika, A.,
V. Guyot, and J. F. Nicolas.
1996.
Transfer of single gene-containing long terminal repeats into the genome of mammalian cells by a retroviral vector carrying the cre gene and the loxP site.
J. Virol.
70:1792-1798[Abstract/Free Full Text].
|
| 8.
|
Cosset, F. L.,
Y. Takeuchi,
J. L. Battini,
R. A. Weiss, and M. K. L. Collins.
1995.
High-titer packaging cells producing recombinant retroviruses resistant to human serum.
J. Virol.
69:7430-7436[Abstract/Free Full Text].
|
| 9.
|
Emi, N.,
T. Friedmann, and J. K. Yee.
1991.
Pseudotype formation of murine leukemia virus with the G protein of vesicular stomatitis virus.
J. Virol.
65:1202-1207[Abstract/Free Full Text].
|
| 10.
|
Flowers, C. C.,
C. Woffendin,
J. Petryniak,
S. Yang, and G. Nabel.
1997.
Inhibition of recombinant human immunodeficiency virus type 1 replication by a site-specific recombinase.
J. Virol.
71:2685-2692[Abstract/Free Full Text].
|
| 11.
|
Fujiwara, K. T.,
K. Ashida,
H. Nishina,
H. Iba,
N. Miyajima,
M. Nishizawa, and S. Kawai.
1987.
The chicken c-fos gene: cloning and nucleotide sequence analysis.
J. Virol.
61:4012-4018[Abstract/Free Full Text].
|
| 12.
|
Gu, H.,
Y. Zou, and K. Rajewsky.
1993.
Independent control of immunoglobulin switch recombination at individual switch regions evidenced through Cre-loxP-mediated gene targeting.
Cell
73:1155-1164[Medline].
|
| 13.
|
Haapala, D. K.,
W. G. Robey,
S. D. Oroszlan, and W. P. Tsai.
1985.
Isolation from cats of an endogenous type C virus with a novel envelope glycoprotein.
J. Virol.
53:827-833[Abstract/Free Full Text].
|
| 14.
|
Kanegae, Y.,
M. Makimura, and I. Saito.
1994.
A simple and efficient method for purification of infectious recombinant adenovirus.
Jpn. J. Med. Sci. Biol.
47:157-166[Medline].
|
| 15.
|
Kanegae, Y.,
G. Lee,
Y. Sato,
M. Tanaka,
M. Nakai,
T. Sakaki,
S. Sugano, and I. Saito.
1995.
Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase.
Nucleic Acids Res.
23:3816-3821[Abstract/Free Full Text].
|
| 16.
|
Kanegae, Y.,
K. Takamori,
Y. Sato,
G. Lee,
M. Nakai, and I. Saito.
1996.
Efficient gene activation system on mammalian cell chromosomes using recombinant adenovirus producing Cre recombinase.
Gene
181:207-212[Medline].
|
| 17.
|
Marshall, E.
1995.
Gene therapy's growing pains.
Science
269:1050-1055[Free Full Text].
|
| 18.
|
Mastromarino, P.,
C. Conti,
P. Goldoni,
B. Hauttecoeur, and N. Orsi.
1987.
Characterization of membrane components of the erythrocyte involved in vesicular stomatitis virus attachment and fusion at acidic pH.
J. Gen. Virol.
68:2359-2369[Abstract/Free Full Text].
|
| 19.
|
Miller, A. D.
1996.
Cell-surface receptors for retroviruses and implications for gene transfer.
Proc. Natl. Acad. Sci. USA
93:11407-11413[Abstract/Free Full Text].
|
| 20.
|
Miller, D. G.,
M. A. Adam, and A. D. Miller.
1990.
Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection.
Mol. Cell. Biol.
10:4239-4242[Abstract/Free Full Text].
|
| 21.
|
Niwa, H.,
K. Yamamura, and J. Miyazaki.
1991.
Efficient selection for high-expression transfectants with a novel eukaryotic vector.
Gene
108:193-200[Medline].
|
| 22.
|
Ory, D. S.,
B. A. Neugeboren, and R. C. Mulligan.
1996.
A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes.
Proc. Natl. Acad. Sci. USA
93:11400-11406[Abstract/Free Full Text].
|
| 23.
|
Roe, T.,
T. C. Reynolds,
G. Yu, and P. O. Brown.
1993.
Integration of murine leukemia virus DNA depends on mitosis.
EMBO J.
12:2099-2108[Medline].
|
| 24.
|
Rose, J. K., and C. J. Gallione.
1981.
Nucleotide sequences of the mRNAs encoding the vesicular stomatitis virus G and M proteins determined from cDNA clones containing the complete coding regions.
J. Virol.
39:519-528[Abstract/Free Full Text].
|
| 25.
|
Rose, J. K., and J. E. Bergmann.
1982.
Expression from cloned cDNA of cell-surface secreted forms of the glycoprotein of vesicular stomatitis virus in eucaryotic cells.
Cell
30:753-762[Medline].
|
| 26.
|
Russ, A. P.,
C. Friedel,
M. Grez, and H. von Melchner.
1996.
Self-deleting retrovirus vectors for gene therapy.
J. Virol.
70:4927-4932[Abstract/Free Full Text].
|
| 27.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
.
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 28.
|
Schlegel, R.,
T. S. Tralka,
M. C. Willingham, and I. Pastan.
1983.
Inhibition of VSV binding and infectivity by phosphatidylserine: is phosphatidylserine a VSV-binding site?
Cell
32:639-646[Medline].
|
| 29.
|
Shyu, A. B.,
M. E. Greenberg, and J. G. Belasco.
1989.
The c-fos transcript is targeted for rapid decay by two distinct mRNA degradation pathways.
Genes Dev.
3:60-72[Abstract/Free Full Text].
|
| 30.
|
Shyu, A. B.,
J. G. Belasco, and M. E. Greenberg.
1991.
Two distinct destabilizing elements in the c-fos message trigger deadenylation as a first step in rapid mRNA decay.
Genes Dev.
5:221-231[Abstract/Free Full Text].
|
| 31.
|
Takeuchi, Y.,
F. L. Cosset,
P. J. Lachmann,
H. Okada,
R. A. Weiss, and M. K. L. Collins.
1994.
Type C retrovirus inactivation by human complement is determined by both the viral genome and producer cell.
J. Virol.
68:8001-8007[Abstract/Free Full Text].
|
| 32.
|
Takeuchi, Y.,
C. D. Porter,
K. M. Strahan,
A. F. Preece,
K. Gustafsson,
F. L. Cosset,
R. A. Weiss, and M. K. Collins.
1996.
Sensitization of cells and retroviruses to human serum by ( 1-3) galactosyltransferase.
Nature (London)
379:85-88[Medline].
|
| 33.
|
Takeuchi, Y.,
S.-H. Liong,
P. D. Bieniasz,
U. Jäger,
C. D. Porter,
T. Friedmann,
M. O. McClure, and R. A. Weiss.
1997.
Sensitization of rhabdo-, lenti-, and spumaviruses to human serum by galactosyl ( 1-3) galactosylation.
J. Virol.
71:6174-6178[Abstract/Free Full Text].
|
| 34.
|
Weiss, R. A.,
D. Boettiger, and H. M. Murphy.
1977.
Pseudotypes of avian sarcoma viruses with the envelope properties of vesicular stomatitis virus.
Virology
76:808-825[Medline].
|
| 35.
|
Westerman, K. A., and P. Leboulch.
1996.
Reversible immortalization of mammalian cells mediated by retroviral transfer and site-specific recombination.
Proc. Natl. Acad. Sci. USA
93:8971-8976[Abstract/Free Full Text].
|
| 36.
|
Yang, Y.,
E. F. Vanin,
M. A. Whitt,
M. Fornerod,
R. Zwart,
R. D. Schneiderman,
G. Grosveld, and A. W. Nienhuis.
1995.
Inducible, high-level production of infectious murine leukemia retroviral vector particles pseudotyped with vesicular stomatitis virus G envelope protein.
Hum. Gene Ther.
6:1203-1213[Medline].
|
| 37.
|
Yee, J. K.,
A. Miyanohara,
P. LaPorte,
K. Bouic,
J. C. Burns, and T. Friedmann.
1994.
A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes.
Proc. Natl. Acad. Sci. USA
91:9564-9568[Abstract/Free Full Text].
|
J Virol, February 1998, p. 1115-1121, Vol. 72, No. 2
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Mizutani, T., Ishizaka, A., Tomizawa, M., Okazaki, T., Yamamichi, N., Kawana-Tachikawa, A., Iwamoto, A., Iba, H.
(2009). Loss of the Brm-Type SWI/SNF Chromatin Remodeling Complex Is a Strong Barrier to the Tat-Independent Transcriptional Elongation of Human Immunodeficiency Virus Type 1 Transcripts. J. Virol.
83: 11569-11580
[Abstract]
[Full Text]
-
Strang, B. L., Takeuchi, Y., Relander, T., Richter, J., Bailey, R., Sanders, D. A., Collins, M. K. L., Ikeda, Y.
(2005). Human Immunodeficiency Virus Type 1 Vectors with Alphavirus Envelope Glycoproteins Produced from Stable Packaging Cells. J. Virol.
79: 1765-1771
[Abstract]
[Full Text]
-
Inoue, M., Tokusumi, Y., Ban, H., Kanaya, T., Shirakura, M., Tokusumi, T., Hirata, T., Nagai, Y., Iida, A., Hasegawa, M.
(2003). A New Sendai Virus Vector Deficient in the Matrix Gene Does Not Form Virus Particles and Shows Extensive Cell-to-Cell Spreading. J. Virol.
77: 6419-6429
[Abstract]
[Full Text]
-
Yamamichi-Nishina, M., Ito, T., Mizutani, T., Yamamichi, N., Watanabe, H., Iba, H.
(2003). SW13 Cells Can Transition between Two Distinct Subtypes by Switching Expression of BRG1 and Brm Genes at the Post-transcriptional Level. J. Biol. Chem.
278: 7422-7430
[Abstract]
[Full Text]
-
Walker, S. J., Pizzato, M., Takeuchi, Y., Devereux, S.
(2002). Heparin Binds to Murine Leukemia Virus and Inhibits Env-Independent Attachment and Infection. J. Virol.
76: 6909-6918
[Abstract]
[Full Text]
-
Mizutani, T., Ito, T., Nishina, M., Yamamichi, N., Watanabe, A., Iba, H.
(2002). Maintenance of Integrated Proviral Gene Expression Requires Brm, a Catalytic Subunit of SWI/SNF Complex. J. Biol. Chem.
277: 15859-15864
[Abstract]
[Full Text]
-
Fang, S.-H., Chiang, B.-L., Wu, M.-H., Iba, H., Lai, M.-Y., Yang, P.-M., Chen, D.-S., Hwang, L.-H.
(2001). Functional Measurement of Hepatitis C Virus Core-Specific CD8+ T-Cell Responses in the Livers or Peripheral Blood of Patients by Using Autologous Peripheral Blood Mononuclear Cells as Targets or Stimulators. J. Clin. Microbiol.
39: 3895-3901
[Abstract]
[Full Text]
-
Barsov, E. V., Payne, W. S., Hughes, S. H.
(2001). Adaptation of Chimeric Retroviruses In Vitro and In Vivo: Isolation of Avian Retroviral Vectors with Extended Host Range. J. Virol.
75: 4973-4983
[Abstract]
[Full Text]
-
Christodoulopoulos, I., Cannon, P. M.
(2001). Sequences in the Cytoplasmic Tail of the Gibbon Ape Leukemia Virus Envelope Protein That Prevent Its Incorporation into Lentivirus Vectors. J. Virol.
75: 4129-4138
[Abstract]
[Full Text]
-
Li, H.-O., Zhu, Y.-F., Asakawa, M., Kuma, H., Hirata, T., Ueda, Y., Lee, Y.-S., Fukumura, M., Iida, A., Kato, A., Nagai, Y., Hasegawa, M.
(2000). A Cytoplasmic RNA Vector Derived from Nontransmissible Sendai Virus with Efficient Gene Transfer and Expression. J. Virol.
74: 6564-6569
[Abstract]
[Full Text]